SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha ...

In aneurysms normally chosen for surveillance, the endovascular technique slowed growth by 70% in the small phase I trial.

The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Nontraditional risk factors, particularly migraine with aura, play a major role in patients under 50 years old.

Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...